Ionis Pharmaceuticals market cap is $6.3 b, and annual revenue was $729.26 m in FY 2020

Ionis Pharmaceuticals Gross profit (FY, 2020)717.3 M

Ionis Pharmaceuticals Gross profit margin (FY, 2020), %98.4%

Ionis Pharmaceuticals Net income (FY, 2020)-486.8 M

Ionis Pharmaceuticals EBIT (FY, 2020)-172.1 M

Ionis Pharmaceuticals Cash, 31-Dec-2020397.7 M

Ionis Pharmaceuticals EV6.3 B

USD | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 108.5m | 99.1m | 102.0m | 147.3m | 214.2m | 283.7m | 346.6m | 507.7m | 599.7m | 1.1b | 729.3m |

| 45% | 32% | 22% | ||||||||

## Cost of goods sold | 1.8m | 4.4m | 11.9m | ||||||||

## Gross profit | 597.9m | 1.1b | 717.3m | ||||||||

| 100% | 100% | 98% | ||||||||

## R&D expense | 145.2m | 157.4m | 158.5m | ||||||||

## General and administrative expense | 11.7m | 12.8m | 12.5m | 14.9m | 20.1m | 37.2m | 48.6m | 108.5m | 244.6m | 286.6m | 354.3m |

## Operating expense total | 156.8m | 170.2m | 171.0m | 14.9m | 20.1m | 37.2m | 48.6m | 108.5m | 659.2m | 752.3m | 889.4m |

## EBIT | (48.4m) | (71.1m) | (68.9m) | (51.7m) | (47.7m) | (75.8m) | (46.3m) | 24.5m | (61.4m) | 365.9m | (172.1m) |

| (45%) | (72%) | (68%) | (35%) | (22%) | (27%) | (13%) | 5% | (10%) | 33% | (24%) |

## Interest expense | 13.2m | 16.7m | 21.2m | ||||||||

## Investment income | 3.4m | 2.4m | 1.8m | 2.1m | 2.7m | 4.3m | 5.4m | 7.8m | 30.2m | 52.2m | 30.6m |

## Pre tax profit | (84.8m) | (74.6m) | (66.6m) | (54.4m) | (87.9m) | (83.6m) | (23.3m) | (76.2m) | 346.8m | (170.0m) | |

## Income tax expense | 92.0k | 11.0k | 2.0k | 2.0k | (15.4m) | 372.0k | 2.9m | (6.0m) | (291.1m) | 43.5m | 316.7m |

## Net Income | (61.3m) | (84.8m) | (65.5m) | (60.6m) | (39.0m) | (88.3m) | (86.6m) | (6.0m) | 273.7m | 294.1m | (486.8m) |

USD | Q2, 2010 |
---|---|

## Financial Leverage | 2.3 x |